Nevertheless, a study was conducted to assess tumor and inflammatory markers and their role in diagnosing lung cancer, such as APOA2, an inflammatory marker that was significantly differentiated between non-small-cell lung cancer (NSCLC) patients and controls, with a sensitivity of 89% [101]. This evidence concerns the gene APOA2 and lung cancer.